The 3 analysts offering 12-month price forecasts for Sonnet Biotherapeutics Holdings Inc have a median target of 75.00, with a high estimate of 100.00 and a low estimate of 44.00. The median estimate represents a +2,499.65% increase from the last price of 2.89.
The current consensus among 3 polled investment analysts is to Buy stock in Sonnet Biotherapeutics Holdings Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.27
Reporting Date Nov 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.